Multinational giants pin hopes on wider insurance coverage

Riding on the government’s plan to broaden coverage of expenses related to the so-called four major illnesses, which was made public yesterday, multinational drug firms expect that their new anticancer drugs with a high price tag will be more easily covered by national health insurance, with a hope that the scope of existing indications will be further expanded.

Under the plan, patients’ ave...